Advertisement
Advertisement
ANIX
Anixa Biosciences, Inc.
2.78
USDSponsored
+0.03
+1.09%
Sep 24, 15:59 UTC -4
Closed
Pre-Market
2.81
+0.03
+0.90%
ANIX Earnings Reports
Positive Surprise Ratio
ANIX beat 23 of 32 last estimates.
72%
Next Report
Date of Next Report
Jan 11, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.08
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/-11.11%
Anixa Biosciences, Inc. earnings per share and revenue
On Sep 09, 2026, ANIX reported earnings of -0.08 USD per share (EPS) for Q3 26, beating the estimate of -0.08 USD, resulting in a 8.78% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.83% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Anixa Biosciences, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Anixa Biosciences, Inc. reported EPS of -$0.08, beating estimates by 8.78%, and revenue of $0.00, 0% as expectations.
How did the market react to Anixa Biosciences, Inc.'s Q3 2026 earnings?
The stock price moved down -2.83%, changed from $2.83 before the earnings release to $2.75 the day after.
When is Anixa Biosciences, Inc. expected to report next?
The next earning report is scheduled for Jan 11, 2027.
What are the forecasts for Anixa Biosciences, Inc.'s next earnings report?
Based on --
analysts, Anixa Biosciences, Inc. is expected to report EPS of -$0.08 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.